Research & Development

Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH

Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.

FDA grants traditional approval to Novartis’ Fabhalta for IgAN

The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.

Novartis and Chai Discovery collaborate on antibody identification

Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.

Apertura and NIH institutes to test gene therapy for NPC1

Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1).

Sino and AstraZeneca sign licence agreement for TQC3721

AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.

Evogene and Tel Aviv University launch drug discovery initiative

Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research.

FDA grants rare paediatric designation to Vanda’s CMT2S therapy

The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).

Biocytogen and Whitehawk partner to develop ADCs

Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.

Vertex signs agreement to acquire Crinetics for $10bn

Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.